{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:49:01Z","timestamp":1788497341476,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>\n                    Bladder cancer is the 4\n                    <jats:sup>th<\/jats:sup>\n                    leading cancer in men. Tumor resection followed by bladder instillation of Bacillus Calmette-Gu\u00e9rin (BCG) is the primary treatment for high-risk patients with Non-Muscle Invasive Bladder Cancer (NMIBC) to prevent recurrence and progression to muscle-invasive disease. This treatment, however, lacks efficiency and causes severe adverse effects. Mannose residues are expressed on bladder surfaces and their levels were indicated to be higher in bladder cancer. Intravesical instillations of a recombinant\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    (PA) overexpressing the mannose-sensitive hemagglutination fimbriae (PA-MSHA), and of a mannose-specific lectin-drug conjugate showed efficiency against NMIBC in murine models of bladder cancer. Urothelial mannosylation facilitates bladder colonization by Uropathogenic\n                    <jats:italic>E. coli<\/jats:italic>\n                    (UPEC)\n                    <jats:italic>via<\/jats:italic>\n                    the interaction with the FimH mannose lectin, positioned at the tip of type 1 fimbria. A recombinant BCG strain overexpressing FimH on its outer surface, exhibited higher attachment and internalization to bladder cancer cells and increased effectivity in treating bladder cancer in mice. Investigating the pattern of mannose expression in NMIBC is important for improving treatment. Here, using tissue microarrays containing multiple normal and cancerous bladder samples, and lectins, we confirm that human bladder cancer cells express high mannose levels. Using UPEC mutants lacking or overexpressing type 1 fimbria, we also demonstrate that tumor-induced hypermannosylation increases type 1 fimbria mediated UPEC attachment to human and mouse bladder cancer. Our results provide an explanation for the effectiveness of PA-MSHA and the FimH-overexpressing BCG and support the hypothesis that mannose-targeted therapy holds potential for improving bladder cancer treatment.\n                  <\/jats:p>","DOI":"10.3389\/fcimb.2022.968739","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T01:41:49Z","timestamp":1661910109000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["High mannose level in bladder cancer enhances type 1 fimbria\u2013mediated attachment of uropathogenic E. coli"],"prefix":"10.3389","volume":"12","author":[{"given":"Naseem","family":"Maalouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamutal","family":"Gur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Yutkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Scaiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Mandelboim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilad","family":"Bachrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2017.00295","article-title":"Tumor targeting by fusobacterium nucleatum: A pilot study and future perspectives","volume":"7","author":"Abed","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur. Urol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of bacillus calmette-gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur. Urol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur. Urol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114295","article-title":"Advances in salmonella typhimurium-based drug delivery system for cancer therapy","volume":"185","author":"Chen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: A systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J. Urol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0924-8579(03)00236-x","article-title":"Virulence factors of uropathogenic escherichia coli","volume":"22","author":"Emody","year":"2003","journal-title":"Int. J. antimicrob. Agents"},{"key":"B8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.1016\/j.vaccine.2008.06.092","article-title":"The use of mycobacterial adjuvant-based agents for immunotherapy of cancer","volume":"26","author":"Grange","year":"2008","journal-title":"Vaccine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1128\/IAI.70.7.3344-3354.2002","article-title":"Assessment of virulence of uropathogenic escherichia coli type 1 fimbrial mutants in which the invertible element is phase-locked on or off","volume":"70","author":"Gunther","year":"2002","journal-title":"Infect. Immun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.chom.2013.11.004","article-title":"Natural killer cell-mediated host defense against uropathogenic e. coli is counteracted by bacterial hemolysinA-dependent killing of NK cells","volume":"14","author":"Gur","year":"2013","journal-title":"Cell Host Microbe"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1099\/00221287-147-5-1383","article-title":"Assessment of GFP fluorescence in cells of streptococcus gordonii under conditions of low pH and low oxygen concentration","volume":"147","author":"Hansen","year":"2001","journal-title":"Microbiology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/asia.202200342","article-title":"Mannose-targeting concanavalin a-epirubicin conjugate for targeted intravesical chemotherapy of bladder cancer","volume":"17","author":"Huo","year":"2022","journal-title":"Chemistry\u2014An Asian J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-Unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","article-title":"Bladder cancer","volume":"374","author":"Kaufman","year":"2009","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1099\/mic.0.28588-0","article-title":"Functional characterization of the FimH adhesin from salmonella enterica serovar enteritidis","volume":"152","author":"Kisiela","year":"2006","journal-title":"Microbiology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1038\/onc.2010.70","article-title":"Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner","volume":"29","author":"Liu","year":"2010","journal-title":"Oncogene"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imm.13330","article-title":"The glycobiology of uropathogenic e. coli infection: the sweet and bitter role of sugars in urinary tract immunity","volume":"164","author":"Lupo","year":"2021","journal-title":"Immunology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009314","article-title":"A host receptor enables type 1 pilus-mediated pathogenesis of escherichia coli pyelonephritis","volume":"17","author":"McLellan","year":"2021","journal-title":"PloS Pathog."},{"key":"B20","first-page":"285","article-title":"Bladder cancer: a review of diagnosis and management","volume":"92","author":"Metts","year":"2000","journal-title":"J. Natl. Med. Assoc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/jjco\/hyt086","article-title":"Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer","volume":"43","author":"Miyazaki","year":"2013","journal-title":"Japanese J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.22038\/IJBMS.2021.53691.12079","article-title":"Type1 and 3 fimbriae phenotype and genotype as suitable markers for uropathogenic bacterial pathogenesis via attachment, cell surface hydrophobicity, and biofilm formation in catheter-associated urinary tract infections (CAUTIs)","volume":"24","author":"Mohammad Zadeh","year":"2021","journal-title":"Iranian J. Basic Med. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1464-410x.1987.tb05002.x","article-title":"Histochemical study of lectin binding in neoplastic and non-neoplastic urothelium","volume":"60","author":"Neal","year":"1987","journal-title":"Br. J. Urol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cncr.28397","article-title":"Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the united states: 1988 to 2006","volume":"120","author":"Nielsen","year":"2014","journal-title":"Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.urolonc.2008.10.024","article-title":"Optimizing BCG therapy","volume":"27","author":"O'Donnell","year":"2009","journal-title":"Urologic. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41579-018-0007-2","article-title":"Glycointeractions in bacterial pathogenesis","volume":"16","author":"Poole","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.UTI-0015-2012","article-title":"Virulence and fitness determinants of uropathogenic escherichia coli","volume":"3","author":"Subashchandrabose","year":"2015","journal-title":"Microbiol. Spectr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF00257180","article-title":"Distribution of concanavalin a binding sites on normal human urinary bladder mucosa and bladder tumors by transmission and scanning electron microscopy and X-ray microanalysis","volume":"12","author":"Takayama","year":"1984","journal-title":"Urol. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/rru.s7237","article-title":"Emerging intravesical therapies for management of nonmuscle invasive bladder cancer","volume":"2","author":"Tomaszewski","year":"2010","journal-title":"Open Access J. Urol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/glycob\/cwz001","article-title":"Lectins as possible tools for improved urinary bladder cancer management","volume":"29","author":"Vi\u0161njar","year":"2019","journal-title":"Glycobiology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00262-021-03063-7","article-title":"Intravesical pseudomonas aeruginosa mannose-sensitive hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model","volume":"71","author":"Wang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1016\/j.juro.2007.07.118","article-title":"The expression level of ligands for natural killer cell receptors predicts response to bacillus calmette-guerin therapy: a pilot study","volume":"178","author":"Yutkin","year":"2007","journal-title":"J. Urol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100427","article-title":"Protocol for live enhanced resolution confocal imaging of dendritic spinule dynamics in primary mouse cortical neuron culture","volume":"2","author":"Zaccard","year":"2021","journal-title":"STAR Protoc."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003939","article-title":"FimH confers mannose-targeting ability to bacillus calmette-guerin for improved immunotherapy in bladder cancer","volume":"10","author":"Zhang","year":"2022","journal-title":"J. ImmunoTherap. Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1242\/jcs.114.22.4095","article-title":"Uroplakin ia is the urothelial receptor for uropathogenic escherichia coli: evidence from in vitro FimH binding","volume":"114","author":"Zhou","year":"2001","journal-title":"J. Cell Sci."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.968739\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T01:41:56Z","timestamp":1661910116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.968739\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":36,"alternative-id":["10.3389\/fcimb.2022.968739"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.968739","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"article-number":"968739"}}